Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer Journal Article


Authors: Germain, C.; Gnjatic, S.; Tamzalit, F.; Knockaert, S.; Remark, R.; Goc, J.; Lepelley, A.; Becht, E.; Katsahian, S.; Bizouard, G.; Validire, P.; Damotte, D.; Alifano, M.; Magdeleinat, P.; Cremer, I.; Teillaud, J. L.; Fridman, W. H.; Sautès-Fridman, C.; Dieu-Nosjean, M. C.
Article Title: Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer
Abstract: Rationale: It is now well established that immune responses can take place outside of primary and secondary lymphoid organs. We previously described the presence of tertiary lymphoid structures (TLS) in patients with non-small cell lung cancer (NSCLC) characterized by clusters of mature dendritic cells (DCs) and T cells surrounded by B-cell follicles. We demonstrated that the density of these mature DCs was associated with favorable clinical outcome. Objectives: To study the role of follicular B cells in TLS and the potential link with a local humoral immune response in patients with NSCLC. Methods: The cellular composition of TLS was investigated by immunohistochemistry. Characterization of B-cell subsets was performed by flow cytometry. A retrospective study was conducted in two independent cohorts of patients. Antibody specificity was analyzed by ELISA. Measurements and Main Results: Consistent with TLS organization, all stages of B-cell differentiation were detectable in most tumors. Germinal center somatic hypermutation and class switch recombination machineries were activated, associated with the generation of plasma cells. Approximately half of the patients showed antibody reactivity against up to 7 out of the 33 tumor antigens tested. A high density of follicular B cells correlated with long-term survival, both in patients with early-stage NSCLC and with advanced-stage NSCLC treated with chemotherapy. The combination of follicular B cell and mature DC densities allowed the identification of patients with the best clinical outcome. Conclusions: B-cell density represents a new prognostic biomarker for NSCLC patient survival, and makes the link between TLS and a protective B cell-mediated immunity. Copyright © 2014 by the American Thoracic Society.
Keywords: immunohistochemistry; cancer chemotherapy; cancer survival; controlled study; human tissue; major clinical study; advanced cancer; cancer patient; flow cytometry; outcome assessment; antineoplastic agent; cell maturation; dendritic cell; lung non small cell cancer; cohort analysis; cell differentiation; retrospective study; tumor antigen; enzyme linked immunosorbent assay; b lymphocyte; germinal center; plasma cell; somatic hypermutation; early cancer; tumor immunity; antibody specificity; cell density; humoral immunity; non-small cell lung cancer; antibody; immunocompetent cell; lymphoid organ; tumor immunology; cell composition; prognostic marker; long term survival; human; male; female; priority journal; article; follicular b cell; tertiary lymphoid structure
Journal Title: American Journal of Respiratory and Critical Care Medicine
Volume: 189
Issue: 7
ISSN: 1073-449X
Publisher: American Thoracic Society  
Date Published: 2014-04-01
Start Page: 832
End Page: 844
Language: English
DOI: 10.1164/rccm.201309-1611OC
PROVIDER: scopus
PUBMED: 24484236
DOI/URL:
Notes: Cited By (since 1996):1 -- Export Date: 1 May 2014 -- CODEN: AJCME -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Sacha Gnjatic
    113 Gnjatic